ASCO 2020 | Perspectives on the CheckMate 9LA study

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, gives his thoughts on data coming from the CheckMate 9LA study and how the data will impact practice in the UK. The study evaluated nivolumab in combination with ipilimumab + 2 cycles of platinum-doublet chemotherapy vs 4 cycles of chemotherapy as first-line treatment for stage IV/reccurent non-small cell lung cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology),